ArticleData in brief2025
RNA-Seq dataset of wild type and PRC2 mutant mouse embryonic stem cells undergoing ground state conversion.
Article in Data in brief, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- WATER reveals heterochrony of molecular programs underlies developmental failure caused by minor spliceosome inhibition.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Mouse embryonic stem cells (mESCs) represent an exceptional model for understanding how transcriptional responses are regulated by signalling pathways during development. Treatment with a cocktail of MEK and GSK3β inhibitors ("2i") induces ground state pluripotency, characterized by increased self-renewal, reduced DNA methylation, and uniformly high expression of pluripotency markers. Polycomb Repressive Complex 2 (PRC2) is a key developmental regulator controlling stem cell self-renewal and differentiation decisions, and altered expression of PRC2 target genes is a signature of 2i-mediated ground state conversion. Here, we generated a comprehensive RNA sequencing dataset from mESCs subjected to 2i conversion time-course across five time points between 0 and 96 h. We analysed two independently derived wild type lines, and two isogenic Cas9-edited lines carrying loss-of-function mutations in core PRC2 subunits Enhancer of Zeste Homolog 2 (Ezh2) or Embryonic Ectoderm Development (Eed). These data provide a resource to understand the temporal patterns of transcriptional responses to MEK and GSK3β inhibitors and explore the role of PRC2 function in regulation of pluripotency circuit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.